Cargando…

Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma

SIMPLE SUMMARY: Metastatic pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that has limited treatment options. Standard of care treatment involves systemic chemotherapy, although all tumors invariably develop resistance to these cytotoxic therapies. With the advent of genomic seq...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huffman, Brandon M., Ellis, Haley, Jordan, Alexander C., Freed-Pastor, William A., Perez, Kimberly, Rubinson, Douglas A., Sethi, Nilay, Singh, Harshabad, Surana, Rishi, Wolpin, Brian M., Aguirre, Andrew J., Cleary, James M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776746/ https://www.ncbi.nlm.nih.gov/pubmed/36551707 http://dx.doi.org/10.3390/cancers14246223

Ejemplares similares

Replicative stress in gastroesophageal adenocarcinoma is associated with chromosomal instability and sensitivity to DNA damage response inhibitors
por: Sahgal, Pranshu, et al.
Publicado: (2023)

Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer
por: Perez, Kimberly, et al.
Publicado: (2023)

Physical activity in older adults with metastatic gastrointestinal cancer: a pilot and feasibility study
por: Brown, Justin C, et al.
Publicado: (2022)

Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma
por: Cleary, James M., et al.
Publicado: (2022)

Replicative stress in gastroesophageal cancer is associated with chromosomal instability and sensitivity to DNA damage response inhibitors
por: Sahgal, Pranshu, et al.
Publicado: (2023)

Early TP53 Alterations Shape Gastric and Esophageal Cancer Development
por: Sahgal, Pranshu, et al.
Publicado: (2021)

Yes-Associated Protein Mediates Immune Reprogramming in Pancreatic Ductal Adenocarcinoma
por: Murakami, Shigekazu, et al.
Publicado: (2016)

G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans
por: Cardot-Ruffino, Victoire, et al.
Publicado: (2023)

USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities
por: Perurena, Naiara, et al.
Publicado: (2023)

Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial
por: Huffman, Brandon M., et al.
Publicado: (2023)

Pancreatic Adenocarcinoma: Real World Evidence of Care Delivery in AccessHope Data
por: Barzi, Afsaneh, et al.
Publicado: (2023)

Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?
por: Rémond, M.S., et al.
Publicado: (2022)

Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk
por: Hamada, Tsuyoshi, et al.
Publicado: (2019)

Metastatic Pancreatic Adenocarcinoma During Pregnancy
por: Davis, Jessica, et al.
Publicado: (2016)

Metastatic Pancreatic Adenocarcinoma to Umbilical Skin
por: Aghighi, Maryam, et al.
Publicado: (2022)

Applied precision medicine in metastatic pancreatic ductal adenocarcinoma
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy
por: Fulop, Daniel J., et al.
Publicado: (2023)

Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival
por: Morales-Oyarvide, Vicente, et al.
Publicado: (2017)

Real-Life Results of Palliative Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
por: Varzaru, Bianca, et al.
Publicado: (2023)

Dilemma of first line regimens in metastatic pancreatic adenocarcinoma
por: Ghosn, Marwan, et al.
Publicado: (2016)

Prognostic Scoring Index for Patients with Metastatic Pancreatic Adenocarcinoma
por: Park, Hyung Soon, et al.
Publicado: (2016)

The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma
por: Houg, Demi S., et al.
Publicado: (2018)

Metastatic Pancreatic Adenocarcinoma Presenting as a Klatskin Tumor
por: Munis, Assad, et al.
Publicado: (2018)

Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
por: Frampton, James E.
Publicado: (2020)

MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma
por: Maddipati, Ravikanth, et al.
Publicado: (2022)

Metastatic involvement of skeletal muscle from gastric adenocarcinoma
por: Aguirre, L E, et al.
Publicado: (2019)

Isolated metastatic pancreatic adenocarcinoma to the uterine cervix: A case report
por: Hartsough, Emily M., et al.
Publicado: (2019)

Elevated circulating branched chain amino acids are an early event in pancreatic adenocarcinoma development
por: Mayers, Jared R., et al.
Publicado: (2014)

A Long-Term Survivor of Metastatic Pancreatic Adenocarcinoma: Free of Recurrence 12 Years After Treatment of Oligometastatic Disease
por: Stahl, John M, et al.
Publicado: (2017)

Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma
por: Raj, Deepak, et al.
Publicado: (2019)

Plasma inflammatory cytokines and survival of pancreatic cancer patients
por: Babic, A., et al.
Publicado: (2018)

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma
por: Péron, Julien, et al.
Publicado: (2016)

Correction to: Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
por: Frampton, James E.
Publicado: (2020)

Treatment Options for Germline BRCA-Mutated Metastatic Pancreatic Adenocarcinoma
por: Grzelak, Doreen
Publicado: (2021)

Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives
por: Lellouche, Lisa, et al.
Publicado: (2021)

Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma
por: Gautam, Shailendra K., et al.
Publicado: (2023)

Effect of High-Dose vs Standard-Dose Vitamin D(3) Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial
por: Brown, Justin C., et al.
Publicado: (2020)

Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
por: Corrie, P. G., et al.
Publicado: (2020)

Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
por: Sinha, Meenal, et al.
Publicado: (2023)

Pancreatic ductal adenocarcinoma in colonic wall: metastatic disease or cancerized pancreatic ectopic tissue?
por: Gallo, Graziana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lufst50mmonbkp5vvpffosv9b0